earliest
immun
respons
activ
acut
human
immunodefici
viru
type
infect
ahi
exert
critic
influenc
subsequ
viru
spread
contain
time
frame
compon
innat
immun
system
macrophag
dc
nk
cell
bdefensin
complement
antimicrobi
factor
implic
modul
hiv
infect
may
play
particularli
import
role
proteomicsbas
screen
perform
cohort
sampl
avail
time
point
prior
earliest
posit
hiv
detect
abil
select
factor
found
elev
plasma
ahi
inhibit
replic
analyz
use
vitro
pbmc
dc
infect
model
analysi
uniqu
plasma
donor
panel
span
eclips
viral
expans
phase
reveal
earli
alter
plasma
protein
ahi
induct
acut
phase
protein
serum
amyloid
asaa
occur
earli
day
prior
first
detect
plasma
viral
rna
consider
prior
elev
system
cytokin
level
furthermor
proteolyt
fragment
aat
term
viru
inhibitori
peptid
virip
observ
plasma
coincid
viremia
asaa
virip
antivir
activ
vitro
quantit
plasma
level
indic
circul
concentr
like
within
rang
inhibitori
activ
result
provid
evid
first
wave
host
antivir
defens
occur
eclips
phase
ahi
prior
system
activ
immun
respons
insight
gain
mechan
action
acutephas
reactant
innat
molecul
hiv
induc
could
exploit
futur
develop
effici
prophylact
vaccin
strategi
although
human
immunodefici
viru
type
induc
chronic
infect
ultim
culmin
develop
acquir
immunodefici
syndrom
recogn
critic
damag
host
immun
system
mediat
acut
phase
infect
exponenti
burst
viral
replic
take
place
associ
massiv
deplet
central
memori
cell
pool
prophylact
strategi
combat
infect
thu
need
modul
event
earliest
stage
infect
lead
impact
acut
viral
burst
prompt
urgent
need
understand
virushost
interact
occur
window
opportun
adapt
respons
known
play
import
role
contain
acut
burst
viral
replic
ahi
event
earliest
stage
infect
also
like
heavili
influenc
compon
innat
immun
system
includ
cellular
determin
effici
viral
entri
replic
within
host
cell
allel
rant
cx
influenc
host
resist
suscept
hiv
infect
interact
virion
dendrit
cell
dc
earli
viru
transmiss
outcom
includ
virion
destruct
follow
bind
langerin
rest
langerhan
cell
effici
viral
transmiss
cell
follow
bind
dcsign
subepitheli
dc
trigger
dc
via
interact
tlr
produc
cytokineschemokin
may
mediat
antivir
activ
may
also
drive
immunopatholog
immun
activ
includ
cellular
apoptosi
genet
studi
help
cast
light
vivo
import
certain
compon
innat
immun
system
acuteearli
hiv
infect
includ
associ
express
certain
kir
cognat
hla
allel
resist
andor
control
hiv
replic
implic
nk
cell
control
hiv
replic
furthermor
bdefensin
secret
oral
mucos
epitheli
cell
appear
inhibit
infect
recent
peptid
fragment
deriv
antitrypsin
aat
serin
proteas
inhibitor
acut
phase
protein
present
blood
plasma
shown
inhibit
hiv
host
cell
infect
block
mediat
cell
entri
natur
factor
exist
modul
hiv
infect
proteolyt
product
prostat
phosphatas
present
semen
abil
dramat
enhanc
hiv
infect
much
current
pictur
event
eclips
earliest
virem
phase
acut
infect
deriv
vitro
studi
work
carri
nonhuman
primat
simian
immunodefici
viru
siv
infect
model
critic
initi
stage
infect
difficult
studi
human
avail
plasma
sampl
seri
collect
timefram
span
eclips
viral
expans
phase
hiv
infect
provid
uniqu
opportun
gain
insight
system
activ
immun
respons
time
previou
report
quantifi
array
cytokin
marker
apoptosi
plasma
panel
describ
massiv
system
cytokin
storm
occur
viral
rampup
phase
associ
increas
plasma
level
apoptot
microparticl
importantli
howev
system
elev
apoptosi
marker
cytokin
level
detect
eclips
phase
viru
amplifi
local
infect
site
prior
system
dissemin
studi
use
proteomicsbas
approach
combin
biochem
cell
biolog
assay
character
factor
elev
plasma
earliest
stage
acut
infect
human
describ
increas
plasma
level
acutephas
reactant
proteolyt
process
fragment
antihiv
activ
eclips
phase
prior
detect
hiv
viremia
first
increas
system
cytokin
level
may
repres
earliest
system
host
antivir
respons
activ
follow
infect
elev
plasma
level
acut
phase
marker
ahi
prior
detect
viremia
sampl
collect
sequenti
time
point
span
eclips
viral
rampup
phase
us
plasma
donor
acquir
infect
studi
gain
insight
kinet
earliest
system
antivir
defens
activ
acut
phase
infect
plasma
typic
obtain
donor
interv
plasma
panel
test
rtpcr
analysi
viral
rna
titer
time
cours
differ
donor
align
rel
time
point
viremia
first
reach
level
detect
convent
assay
rna
copi
ml
fig
panel
cover
timefram
around
rel
current
thought
eclips
phase
infect
rang
henc
panel
like
includ
sampl
collect
time
point
prior
acquisit
infect
onward
order
determin
whether
detect
chang
plasma
protein
peptid
accompani
emerg
viremia
initi
mass
spectrometrybas
screen
perform
three
plasma
donor
panel
fig
analysi
longitudin
malditof
data
reveal
mass
peak
elev
virem
time
point
fig
one
mass
peak
molecular
mass
dalton
mh
found
consider
elev
plasma
fig
sequenc
malditoftof
lcmsm
identifi
mass
peptid
deriv
asaa
fig
fig
semiquantit
analysi
mass
peak
intens
mh
peptid
mass
reveal
peptid
elev
coincid
increas
viremia
subject
immedi
prior
detect
viremia
fig
suggest
asaa
protein
level
elev
time
second
mass
peak
molecular
mass
dalton
mh
identifi
peptid
complement
fig
peak
also
elev
prior
well
viremia
fig
plasma
level
asaa
increas
prior
detect
viremia
ahi
asaa
shown
previous
elev
patient
aid
commonli
use
gener
marker
inflamm
recent
studi
demonstr
asaa
antivir
activ
vitro
therefor
examin
larger
set
plasma
donor
panel
elisa
test
whether
elev
asaa
level
may
gener
featur
associ
acut
infect
induct
relat
increas
plasma
viral
rna
titer
control
establish
baselin
use
statist
analysi
data
also
measur
asaa
level
plasma
panel
five
control
plasma
donor
becom
infect
hiv
fig
baselin
level
asaa
calcul
describ
method
section
vari
individu
gener
analysi
asaa
level
plasma
panel
hivinfect
donor
confirm
asaa
elev
rel
baselin
prior
andor
concurr
within
earliest
detect
viremia
importantli
signific
asaa
elev
ie
fall
predict
interv
observ
prior
viral
rna
copi
ml
subject
fig
subject
group
whole
asaa
level
thu
elev
significantli
prior
time
first
detect
plasma
viremia
p
determin
use
binomi
test
monitor
alter
acut
form
asaa
well
constitut
express
form
csaa
serum
amyloid
acquir
immun
defici
syndrom
aid
remain
major
health
problem
worldwid
affect
predominantli
adult
popul
western
world
develop
countri
particular
despit
tremend
effort
develop
cure
vaccin
confer
protect
human
immunodefici
viru
infect
achiev
satisfactori
manner
date
recent
research
effort
suggest
earliest
immun
respons
activ
exposur
viru
influenc
viru
spread
contain
diseas
progress
studi
panel
donor
provid
plasma
sampl
collect
timefram
span
period
immedi
detect
infect
permit
insight
activ
earliest
system
immun
respons
describ
increas
plasma
level
acutephas
reactant
proteolyt
process
fragment
antivir
activ
vitro
induct
occur
prior
detect
viru
blood
first
increas
system
cytokin
level
may
repres
earliest
system
host
antivir
respons
activ
follow
infect
perform
immunoblot
assay
specif
antibodi
fig
plasma
donor
panel
test
immunoblot
confirm
initi
increas
asaa
level
prior
viral
rampup
addit
first
wave
asaa
induct
occur
prior
detect
viremia
immunoblot
also
confirm
second
intens
phase
elev
observ
six
ten
donor
test
coincid
increas
viral
load
individu
either
low
consist
high
level
asaa
timefram
analyz
contrast
asaa
major
acut
phase
reactant
induc
infect
process
csaa
observ
unmodifi
glycosyl
form
detect
minor
induct
panel
examin
explor
whether
elev
asaa
specif
attribut
infect
examin
plasma
panel
donor
becam
posit
either
hepat
c
viru
hcv
hepat
b
viru
hbv
period
sampl
collect
detect
increas
level
asaa
time
cours
infect
panel
subject
acut
hbv
infect
panel
subject
acut
hcv
infect
fig
fig
b
c
indic
asaa
induct
may
repres
common
host
respons
microbi
infect
comprehens
analysi
liquid
chromatographi
tandem
mass
spectrometri
lcmsm
reveal
number
plasma
compon
includ
complement
factor
apolipoprotein
aat
present
plasma
ahi
tabl
factor
found
elev
plasma
ahi
includ
ctermin
peptid
deriv
aat
residu
refer
virip
tabl
fig
shown
inhibit
entri
host
cell
target
fusion
peptid
seven
plasma
panel
hivinfect
individu
five
panel
uninfect
control
evalu
presenc
virip
tandem
mass
spectrometri
semiquantit
fashion
ion
count
detect
precursor
ion
repres
expect
molecular
mass
virip
correl
viremia
reveal
elev
virip
coincid
initi
increas
viremia
two
seven
plasma
donor
panel
infect
individu
none
five
control
fig
semiquantit
titrat
virip
peptid
mass
spectrometri
indic
amount
detect
correspond
estim
valu
virip
plasma
peak
concentr
fig
consid
sampl
loss
isol
virip
peptid
plasma
effect
virip
concentr
like
rang
low
mgml
approxim
ic
valu
virip
interfer
entri
see
also
appear
virip
plasma
sampl
subject
rais
question
proteolyt
process
aat
may
mediat
condit
previou
studi
indic
mmp
collagenas
elastas
interact
cleav
aat
inspect
region
aat
flank
virip
sequenc
predict
cleavag
site
ntermin
ctermin
end
virip
fig
vitro
digest
purifi
aat
recombin
reveal
degrad
product
kda
detect
immunoblot
consist
ctermin
aat
fragment
contain
virip
fig
subsequ
analysi
carri
use
lcmsm
identifi
peptid
contain
cleavag
site
requir
format
virip
phe
leu
phe
leu
fig
third
cleavag
within
virip
sequenc
pro
met
also
observ
importantli
format
virip
detect
h
time
point
confirm
candid
proteas
involv
gener
peptid
vivo
antivir
activ
factor
elev
plasma
ahi
order
test
potenti
interfer
infect
process
evalu
abil
acut
phase
protein
aat
asaa
creactiv
protein
crp
ctermin
aat
fragment
virip
inhibit
replic
use
vitro
peripher
blood
mononuclear
cell
pbmc
dendrit
cell
dc
infect
model
phaactiv
pbmc
monocytederiv
dendrit
cell
mddc
incub
test
analyt
prior
infect
either
viru
subsequ
replic
monitor
analysi
supernat
level
revers
transcriptas
activ
virip
deriv
near
cterminu
aat
markedli
inhibit
replic
viru
consist
previou
find
fig
contrast
effect
observ
either
fulllength
aat
ctermin
fig
addit
crp
inhibit
replic
either
viru
pbmc
fig
asaa
exhibit
inhibitori
activ
pbmc
infect
system
inhibit
replic
viru
mddc
earli
h
infect
fig
greater
extent
fig
importantli
inhibit
mddc
infect
still
greater
asaa
concentr
well
rang
level
detect
infect
individu
fig
asaa
recent
report
inhibit
mddc
infect
dual
tropic
viru
via
downregul
express
conclud
compon
acut
phase
respons
inde
capac
interfer
infect
therebi
potenti
help
control
viral
dissemin
eclips
phase
avail
sequenti
sampl
plasma
donor
becam
infect
provid
uniqu
opportun
studi
chang
plasma
eclips
viral
expans
phase
acut
infect
recent
studi
describ
induct
cytokin
storm
massiv
cellular
apoptosi
phase
exponenti
viral
replic
proteomicsdriven
approach
use
demonstr
first
time
acut
phase
protein
exhibit
antivir
activ
induc
system
even
prior
first
detect
viremia
also
detect
increas
plasma
cytokin
level
factor
elev
includ
asaa
protein
primarili
synthes
cell
liver
highlevel
product
known
induc
acut
phase
respons
infect
trauma
stress
proinflammatori
cytokin
includ
tnfalpha
notabl
asaa
frequent
elev
biphas
kinet
plasma
subject
acquir
infect
initi
elev
occur
eclips
phase
second
elev
viral
rampup
phase
latter
tempor
coincid
elev
circul
level
multipl
proinflammatori
cytokin
like
reflect
hepat
respons
system
stimulu
initi
elev
plasma
asaa
level
found
occur
significantli
prior
detect
viral
rna
plasma
well
system
elev
detect
plasma
cytokin
chemokin
level
follow
sexual
transmiss
viru
replic
local
genit
rectal
mucosa
spread
drain
lymph
node
subsequ
gutassoci
lymphoid
tissu
galt
mechan
acut
phase
protein
product
trigger
process
current
unknown
may
involv
transfer
induct
factor
liver
includ
proinflammatori
cytokin
produc
local
site
viral
replic
trigger
product
acut
phase
reactant
prior
widespread
viru
dissemin
system
increas
cytokin
level
altern
asaa
produc
extra
hepat
site
asaa
express
report
macrophag
adren
gland
kidney
intestin
albeit
lower
level
compar
hepatocyt
initi
burst
asaa
level
may
also
contribut
subsequ
cytokin
storm
observ
later
system
level
sinc
asaa
shown
induc
array
immunomodulatori
cytokin
includ
monocyt
macrophag
lymphocyt
activ
acut
phase
reactant
may
repres
earli
line
antivir
defens
infect
sinc
asaa
aat
ctermin
peptid
deriv
aat
refer
virip
shown
exert
antivir
activ
vitro
fig
b
howev
acut
phase
protein
induc
respons
inflamm
antivir
properti
observ
crp
fig
also
elev
system
plasma
donor
prior
viremia
data
shown
found
select
inhibit
infect
mddc
pbmc
asaa
abil
inhibit
replic
previous
propos
mediat
downregul
express
capac
inhibit
viru
replic
mddc
pbmc
may
thu
due
fact
mddc
express
low
level
wherea
express
cell
much
higher
unlik
inhibitori
effect
asaa
limit
specif
pathogen
acut
phase
reactant
describ
upregul
number
patholog
process
includ
inflamm
divers
bacteri
viral
infect
consist
observ
mark
elev
asaa
plasma
panel
donor
acutelyinfect
hcv
notabl
asaa
shown
mediat
antivir
activ
viral
pathogen
effect
propos
mediat
mechan
distinct
inhibitori
effect
infect
acut
hcv
infect
asaa
induct
may
stimul
consequ
viral
replic
liver
associ
cytokin
respons
acut
hbv
infect
littl
asaa
elev
observ
may
relat
differ
fig
viremia
viral
load
describ
previous
top
panel
viral
load
second
third
panel
peak
intens
mass
peak
da
da
normal
correspond
peak
intens
observ
first
time
point
bottom
panel
rel
peak
intens
mass
peak
use
standard
illustr
use
compar
ms
acquisit
condit
time
point
arrow
middl
bottom
panel
indic
virem
time
point
solid
circl
show
asaa
protein
level
subjectspecif
background
level
asaa
dot
grey
line
predict
interv
threshold
defin
signific
elev
black
line
calcul
describ
method
section
subject
show
significantli
elev
asaa
level
first
detect
viral
load
b
asaa
csaa
protein
level
sequenti
plasma
sampl
donor
acquir
infect
assess
use
antiasaa
anticsaa
immunoblot
two
set
blot
posit
replic
kinet
hbv
compar
hcv
andor
rel
mute
cytokin
respons
activ
acut
hbv
infect
genet
studi
suggest
polymorph
observ
aat
anoth
compon
acut
phase
respons
link
suscept
infect
aat
initi
report
block
activ
proteas
subsequ
aatderiv
ctermin
peptid
shown
inhibit
ltr
gene
express
vitro
howev
strongest
effect
report
far
exert
virip
gener
proteolyt
product
aat
inhibit
viral
entri
bind
fusion
peptid
activ
low
micromolar
rang
asaa
virip
abl
detect
endogen
level
plasma
rang
capabl
mediat
viral
inhibit
rais
possibl
factor
play
role
combat
viral
replic
particularli
earliest
stage
infect
strong
correl
found
initi
time
asaa
elev
either
r
viral
reproduct
rate
slope
viral
rampup
highest
record
viral
load
subject
studi
nevertheless
relationship
magnitud
dynam
earli
acutephas
protein
product
acut
viral
burst
subsequ
effici
control
viremia
address
futur
studi
larger
cohort
sampl
collect
longer
timefram
extend
earli
infect
interestingli
also
note
level
aat
proteolyt
fragment
plasma
subject
chronicallyinfect
elev
compar
healthi
control
data
shown
suggest
acut
phase
protein
may
also
play
role
chronic
viral
infect
possibl
compon
acut
phase
respons
may
contribut
control
viral
replic
infect
individu
may
also
involv
mediat
resist
infect
instanc
uninfect
individu
shown
elev
level
cleav
form
asaa
suggest
antivir
activ
contribut
resist
infect
evid
literatur
data
suggest
mmp
respons
aat
proteolysi
particular
alter
level
report
correl
infect
breakdown
extracellular
matrix
suggest
aid
dissemin
viru
vitro
experi
confirm
known
cleavag
site
ctermin
part
aat
also
demonstr
virip
gener
despit
presenc
addit
cleavag
site
within
sequenc
peptid
cleavag
site
pro
met
directli
neighbour
activ
site
ser
shown
previous
sensit
oxid
state
met
residu
therebi
protect
virip
degrad
addit
result
support
notion
biolog
function
cleavag
aat
may
sole
inactiv
serin
proteas
function
also
gener
new
proteolyt
peptid
addit
activ
abund
acut
phase
protein
abl
detect
elev
ahi
may
select
exampl
constitutivelyproduc
induc
analyt
play
role
combat
infect
increas
amount
evid
suggest
endogen
factor
exist
inher
inhibitori
activ
toward
infecti
pathogen
includ
antimicrobi
polypeptid
antiproteas
cystatin
also
detect
cervic
mucosa
insight
gain
mechan
action
innat
factor
acut
phase
reactant
induc
consid
novel
vaccin
strategi
therapeut
plasmapheresi
sampl
us
plasma
donor
cohort
use
studi
purchas
zeptometrix
corpor
seracar
life
scienc
donor
recruit
via
septacar
special
donor
program
enrol
plasma
donat
medic
examin
interview
medic
staff
explain
donat
plasma
use
dedic
drug
vaccin
research
perform
research
help
other
studi
approv
oxford
tropic
research
ethic
committe
oxtrec
univers
oxford
nih
offic
extramur
research
nr
bmk
panel
sequenti
sampl
obtain
plasmapheresi
us
plasma
donor
becam
infect
hbv
hcv
control
subject
purchas
zeptometrix
corpor
seracar
life
scienc
store
use
detail
panel
method
use
analysi
hbv
hcv
viral
load
describ
plasma
panel
includ
sampl
collect
prior
detect
plasma
viremia
seroconvers
plasma
panel
hivinfect
individu
tempor
align
rel
common
time
origin
defin
time
point
viral
load
first
reach
detect
level
viral
rna
copi
ml
describ
previous
median
rang
durat
observ
prior
first
detect
hiv
rna
level
panel
use
studi
day
rang
day
plasma
donor
sampl
fraction
use
weak
anion
exchang
wax
magnet
bead
bruker
dalton
bremen
germani
accord
manufactur
recommend
text
analysi
malditoftof
solut
acid
matrix
mg
ethanol
aceton
ml
prepar
freshli
sampl
process
describ
matrix
solut
mix
ratio
ml
aliquot
spot
triplic
anchor
chip
maldi
plate
bruker
dalton
bremen
germani
data
acquir
ultraflex
malditoftof
instrument
bruker
dalton
bremen
germani
laser
power
total
intens
ion
count
reach
spectra
analyz
use
bruker
dalton
flexanalysi
softwar
version
lcm
ms
tandem
mass
spectrometri
analysi
carri
time
point
plasma
viral
rna
first
detect
align
vertic
line
postvirem
time
point
indic
horizont
arrow
c
asaa
csaa
protein
level
sequenti
plasma
sampl
donor
acquir
hcv
infect
top
panel
donor
acquir
hbv
infect
bottom
panel
two
set
blot
posit
time
point
plasma
viral
nucleic
acid
first
detect
align
vertic
line
postvirem
time
point
indic
horizont
arrow
inject
ml
sampl
prepar
describ
nanoacqu
uplc
system
coupl
water
qtof
premier
tandem
mass
spectromet
ms
e
highlow
collis
switch
mode
describ
previous
process
raw
data
perform
use
proteinlynx
global
server
softwar
data
interrog
inhous
mascot
server
version
altern
sampl
analyz
bruker
hctplu
ion
trap
tandem
mass
spectromet
bruker
dalton
bremen
germani
describ
semiquantit
analysi
ms
data
base
measur
peak
height
observ
peptid
mass
assign
asaa
recombin
activ
emd
bioscienc
gibbstown
nj
mg
ml
ad
solut
aat
sigma
aldrich
st
loui
mo
ml
mg
ml
mm
ammonium
bicarbon
buffer
mixtur
incub
aliquot
ml
remov
immunoblot
min
mix
rsb
ml
retain
analysi
immunoblot
carri
follow
gel
electrophoresi
bistri
tristricin
gel
invitrogen
carlsbad
ca
increas
resolut
low
molecular
weight
speci
lcmsm
analysi
carri
min
min
time
point
sampl
follow
desalt
concentr
methanol
chloroform
precipit
analysi
plasma
sampl
use
antisaa
elisa
assay
perform
use
commerci
saa
elisa
kit
abazym
needham
conduct
accord
manufactur
instruct
plasma
sampl
dilut
assay
buffer
obtain
final
concentr
within
linear
rang
assay
ng
ml
inclus
recombin
protein
standard
demonstr
asaa
sensit
detect
assay
csaa
nonreact
final
concentr
ng
ml
infect
assay
use
virus
deriv
infecti
molecular
clone
suppli
john
kapp
christina
jambor
univers
alabama
birmingham
usa
cryopreserv
healthi
donor
pbmc
stimul
ml
pha
sigma
aldrich
st
loui
mo
medium
invitrogen
carlsbad
ca
roch
nutley
nj
medium
adjust
contain
serum
mddc
gener
cultur
cell
isol
buffi
coat
nation
blood
servic
london
uk
use
human
monocyt
isol
kit
ii
medium
never
control
cultur
treat
similar
volum
dmso
optimem
plain
optimem
vehicl
match
addit
inhibitor
pbmc
preincub
inhibitor
h
prior
infect
infect
viru
moi
h
presenc
inhibitor
excess
viru
inhibitor
wash
cell
cultur
medium
plu
ml
supernat
harvest
level
determin
elisa
advanc
bioscienc
laboratori
inc
kensington
md
mddc
preincub
inhibitor
h
prior
infect
moi
h
presenc
inhibitor
washout
inhibitor
excess
viru
cell
cultur
read
supernat
level
describ
statist
analysi
data
viral
inhibit
assay
perform
use
oneway
anova
statist
analysi
elisa
data
plasma
asaa
level
two
statist
test
perform
transform
data
sampl
timecours
five
control
nonhivinfect
plasma
donor
time
point
prior
timecours
hivinfect
plasma
donor
wilcoxon
test
twogroup
comparison
control
vs
hivinfect
p
anova
test
linear
mix
model
group
differ
p
signific
differ
found
control
data
hivinfect
subject
use
determin
baselin
asaa
level
hivinfect
subject
linear
mixedeffect
model
fit
data
estim
subjectspecif
baselin
level
asaa
hivinfect
individu
asaa
valu
upper
predict
bound
consid
significantli
elev
see
fig
twosid
binomi
test
conduct
examin
whether
first
elev
asaa
occur
significantli
addit
test
associ
time
first
asaa
elev
three
differ
paramet
viral
replic
viral
reproduct
rate
r
slope
viral
rampup
highest
record
viral
load
also
perform
use
linear
model
figur
asaa
level
measur
elisa
plasma
panel
control
plasma
donor
plasma
donor
acquir
hbv
infect
donor
acquir
hcv
infect
asaa
level
plasma
panel
five
control
nonhivinfect
plasma
donor
solid
circl
show
asaa
protein
level
subjectspecif
background
level
asaa
dot
grey
line
predict
interv
threshold
defin
signific
elev
black
line
calcul
describ
method
section
b
asaa
level
plasma
panel
three
hbvinfect
donor
graph
time
plot
rel
first
time
point
dna
level
copi
ml
asaa
protein
level
indic
black
squar
solid
black
line
hbv
dna
level
black
triangl
dot
black
line
c
asaa
level
plasma
panel
three
hcvinfect
donor
graph
time
plot
rel
first
time
point
rna
level
copi
ml
asaa
protein
level
indic
black
squar
solid
black
line
hcv
rna
level
black
triangl
dot
black
line
